1. Home
  2. AII vs ETON Comparison

AII vs ETON Comparison

Compare AII & ETON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

AII

American Integrity Insurance Group Inc.

HOLD

Current Price

$17.86

Market Cap

394.3M

Sector

Finance

ML Signal

HOLD

Logo Eton Pharmaceuticals Inc.

ETON

Eton Pharmaceuticals Inc.

HOLD

Current Price

$17.01

Market Cap

411.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
AII
ETON
Founded
2006
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Property-Casualty Insurers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
394.3M
411.9M
IPO Year
2025
2018

Fundamental Metrics

Financial Performance
Metric
AII
ETON
Price
$17.86
$17.01
Analyst Decision
Buy
Strong Buy
Analyst Count
7
3
Target Price
$26.67
$29.67
AVG Volume (30 Days)
129.0K
217.6K
Earning Date
02-24-2026
03-17-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
4.32
N/A
Revenue
$275,530,000.00
$70,316,000.00
Revenue This Year
$33.10
$107.23
Revenue Next Year
$27.55
$29.72
P/E Ratio
$4.15
N/A
Revenue Growth
37.17
102.77
52 Week Low
$15.78
$11.09
52 Week High
$26.36
$23.00

Technical Indicators

Market Signals
Indicator
AII
ETON
Relative Strength Index (RSI) 37.85 67.48
Support Level $17.57 $14.49
Resistance Level $18.36 $15.01
Average True Range (ATR) 0.52 0.66
MACD 0.01 0.29
Stochastic Oscillator 29.47 100.00

Price Performance

Historical Comparison
AII
ETON

About AII American Integrity Insurance Group Inc.

American Integrity Insurance Group Inc is engaged in the property and casualty insurance business. It provides personal residential property insurance for single-family homeowners and condominium owners as well as coverage for vacant dwellings and investment properties, predominantly in Florida. The Company's property and casualty insurance is currently offered in Florida, South Carolina, and Georgia.

About ETON Eton Pharmaceuticals Inc.

Eton Pharmaceuticals Inc is a United States based specialty pharmaceutical company. The company is engaged in developing and commercializing pharmaceutical products to fulfill an unmet patient need. It has four commercial rare disease products, Alkindi Sprinkle for the treatment of adrenocortical insufficiency; Carglumic Acid for the treatment of hyperammonemia, Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of hereditary tyrosinemia type 1 (HT-1). The Company has three additional product candidates in late-stage development: ET-400, ET-600, and ZENEO hydrocortisone autoinjector.

Share on Social Networks: